11.12.26 -- US Pharma Reshoring: The Full Policy Timeline

Biologics face unpredictable risks as complexity grows; evolving testing strategies to broaden detection, address gaps, and strengthen safety confidence without disrupting development or compliance.

Moving innovative science toward patients requires more than a promising laboratory result. Explore how nanoparticles and advanced drug development technologies are translated into practical solutions.

Uncover how tunable expression technology achieves optimal chain pairing and high titers for complex biologics, from four-chain bispecifics to difficult-to-express proteins, using platform processes.

Scale-out manufacturing speeds commercial launch by using modular single-use systems that preserve process consistency, reduce comparability risk, and align capacity with demand.

Characterized by fewer studies, deeper analytical characterization, and integrated process design, the lean biosimilar development model expands market access and brings treatment to patients faster.

A Tufts University analysis modeled the eNPV gains, ROI, and timeline reductions possible when CDMO and CRO functions are consolidated, finding consistent benefits across mAbs.

In this two-minute preview, we take a high-level look at the entire gene therapy development journey — from discovery and preclinical research to process development, manufacturing, and more.

Discover how a tailored development approach transformed a complex therapeutic protein into a candidate ready for early-stage clinical trials.